Healthy Skepticism Library item: 10987

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Editorial .
Macular degeneration, patients' groups, and pharma
The Lancet 2007 Jul 21; 370:(9583):194
http://www.thelancet.com/journals/lancet/article/PIIS0140673607610988/fulltext

Notes:

… Patients and patients’ groups do not take NICE’s decisions lying down. The AMD Alliance-a global non-profit coalition of AMD-related patients’ organisations-has launched a campaign against the preliminary NICE guidance. Its website reads: “British AMD patients facing draconian situation-cruel watchdog is condemning 20000â€. But no similar campaign has been launched to lobby Genentech and the companies involved in marketing bevacizumab or ranibizumab to fund a trial comparing the two. Such a move would show that the AMD Alliance is serious about exploring all possibilities for people with AMD.